Royal Bank of Canada
FTH

Royal Bank of Canada’s Faeth Therapeutics FTH Stock Holding History

Royal Bank of Canada’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Buy
+509
New +$11.8K ﹤0.01% 6555
2024
Q3 		– Sell
-12
Closed – – 7391
2024
Q2 		$0 Buy
12
+9
+300% +$187 ﹤0.01% 7495
2024
Q1 		$0 Sell
3
-24
-89% -$414 ﹤0.01% 7544
2023
Q4 		$0 Buy
27
+15
+125% +$205 ﹤0.01% 7542
2023
Q3 		$0 Sell
12
-12
-50% -$258 ﹤0.01% 7540
2023
Q2 		$1K Buy
24
+21
+700% +$615 ﹤0.01% 7074
2023
Q1 		$0 Buy
+3
New +$89 ﹤0.01% 7440
2022
Q4 		– Sell
-4
Closed -$118 – 7676
2022
Q3 		$0 Buy
+4
New +$157 ﹤0.01% 7824
2022
Q2 		– Sell
-64
Closed -$3K – 7690
2022
Q1 		$3K Sell
64
-153
-71% -$12.2K ﹤0.01% 7400
2021
Q4 		$26K Buy
217
+96
+79% +$14.3K ﹤0.01% 6683
2021
Q3 		$25K Buy
121
+87
+256% +$15.8K ﹤0.01% 6582
2021
Q2 		$7K Sell
34
-3
-8% -$741 ﹤0.01% 6985
2021
Q1 		$11K Buy
+37
New +$12.4K ﹤0.01% 6772

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Royal Bank of Canada's FTH Position: Q2 2026 in Review

Royal Bank of Canada opened a new position in Faeth Therapeutics (FTH) in Q2 2026: 509 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #6555 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in FTH as recently as Q2 2024.

Royal Bank of Canada first reported a position in FTH in Q1 2021 and has held it in 13 quarters since. The position peaked at $26K in Q4 2021. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Royal Bank of Canada held 509 shares of Faeth Therapeutics worth $13K as of Q2 2026.
  • Faeth Therapeutics was a new Royal Bank of Canada position in Q2 2026.
  • Faeth Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6555 holding.
  • Royal Bank of Canada first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • Royal Bank of Canada's Faeth Therapeutics position peaked at $26K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.